Chinese Journal of Cancer Research

, Volume 18, Issue 4, pp 241–245 | Cite as

A liver-tumor adhesion peptide from random phage display library

  • Wu Miao  (吴淼)
  • Du Bing  (杜冰)
  • Wang Lei  (汪磊)
  • Zhou Zhong-liang  (周忠良)
  • Qian Min  (钱旻)Email author



To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7502 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma targeting therapy.


Phage A54 was confirmed by ELISA. Biotin and FAM labeled A54 peptides were identified and localized by means of immunohistochemistry and immunocytochemistry.


A54 peptide could target the liver-tumor tissue in vivo and adhere to several liver-tumor cells in vitro. FAM-labeled A54 peptides were localized on the membrane surface of liver-tumor cells.


Synthesized A54 peptide obtained from in vivo phage display technology still kept special ability to adhere liver-tumor cell in vivo and in vitro. The A54 peptide could be a candidate carrier for hepatocarcinoma targeting therapy.

Key words

A54 peptide Identification localization Medicine carrier 

CLC number



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Jain RK. The next frontier of molecular medicine: delivery of therapeutics[J]. Nat Med 1998; 4: 655–677.PubMedCrossRefGoogle Scholar
  2. [2]
    Johnson DH. Targeted therapy in non-small cell lung cancer: myth and reality[J]. Lung Cancer 2003; 41: S3–S8.PubMedCrossRefGoogle Scholar
  3. [3]
    Arap W, Pasqualini RP, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model[J]. Science 1998; 279: 377–380.PubMedCrossRefGoogle Scholar
  4. [4]
    Tang ZY. Practical Oncology (Shi-Yong-Zhong-Liu-Xue) [M]. 2ed. Shanghai: Fudan University Press, 2003; p534–535.Google Scholar
  5. [5]
    Veronese ML, Peter JO, O’ Dwyer PJ, et al. Monoclonal antibodies in the treatment of colorectal cancer[J]. Eur J Cancer 2004; 40: 1292–1301.PubMedCrossRefGoogle Scholar
  6. [6]
    Zhang J, Spring H, Schwab M, et al. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display[J]. Cancer Lett 2001; 171: 153–164.PubMedCrossRefGoogle Scholar
  7. [7]
    Du B, Qian M, Zhou ZL, et al. In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library[J]. Biochem Biophys Res Commun 2006; 342: 956–962.PubMedCrossRefGoogle Scholar
  8. [8]
    Du Bing, Yu J, Zhou ZL, et al. Selection of the peptides specifically binding to hepatoma by using phage display in vivo[J]. Chin J Oncol 2005; 27: 645–647.Google Scholar
  9. [9]
    Zurita AJ, Arap W, Pasqualini R, et al. Mapping tumor vascular diversity by screening phage display libraries[J]. J Control Release 2003; 91: 183–186.PubMedCrossRefGoogle Scholar
  10. [10]
    Scott JK. Smith GP. Searching for peptide ligands with an epitope library[J]. Science 1990; 249: 386–389.PubMedCrossRefGoogle Scholar
  11. [11]
    Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display[J]. J Biol Chem 1999; 274: 11593–11598.PubMedCrossRefGoogle Scholar
  12. [12]
    Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display[J]. Semin Cancer Biol 2000; 10: 435–442.PubMedCrossRefGoogle Scholar
  13. [13]
    Arap W, Kolonin MG, Trepel M. Steps toward mapping the human vasculature by phage display[J]. Nat Med 2002; 8: 121–127.PubMedCrossRefGoogle Scholar
  14. [14]
    Nicolella D, Maione P, Gridelli C. Targetd therapies: focus on a new strategy for gastyrointestinal tumors[J]. Crit Rev Oncol Hematol 2003; 47: 261–271.PubMedGoogle Scholar
  15. [15]
    Nilsson F, Tarli L, Viti F, et al. The use of phage display for the development of tumor targeting agents[J]. Adv Drug Deliv Rev 2000; 43: 165–196.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association 2006

Authors and Affiliations

  • Wu Miao  (吴淼)
    • 1
  • Du Bing  (杜冰)
    • 1
  • Wang Lei  (汪磊)
    • 1
  • Zhou Zhong-liang  (周忠良)
    • 1
  • Qian Min  (钱旻)
    • 1
    Email author
  1. 1.School of Life ScienceEast China Normal UniversityShanghaiChina

Personalised recommendations